Janessa Laskin

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +11

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers

Lori J. Wirth, Eric J. Sherman, Bruce Robinson et al. · New England Journal of Medicine · 2020 · 773 citations · Full text

Medicine, Endocrinology, Oncology +16

Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution

Michelle Chan‐Seng‐Yue, Jaeseung Kim, Gavin W. Wilson et al. · Nature Genetics · 2020 · 689 citations · Full text

Medicine, Molecular Biology, Oncology +17

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Luis Paz‐Ares, E.H. Tan, Kenneth J. O’Byrne et al. · Annals of Oncology · 2017 · 522 citations · Full text

Medicine, Oncology, Pharmacology +16

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han et al. · Annals of Oncology · 2020 · 276 citations · Full text

Medicine, Oncology, Pharmacology +15